Strong Balance SheetA high equity ratio and low leverage provide durable financial flexibility, allowing the company to fund R&D, absorb setbacks, and pursue partnerships without heavy refinancing. Over the next 2–6 months this stability supports sustained investment in product commercialization.

High And Improving MarginsSustained high gross margins and improving EBIT/EBITDA margins indicate efficient production and cost management. This margin profile supports reinvestment in development and commercialization and provides a buffer if revenue growth falters in the medium term.

Focused IP-driven Business ModelA business mix of product sales, licensing and collaborative development diversifies revenue sources and leverages proprietary technology. Durable IP monetization and partnership channels can scale commercialization and reduce single-channel dependence over several months.

Bears Say

Revenue DeclineA negative year-over-year revenue trend signals challenges in market penetration or product demand. Persistent top-line contraction can pressure margins, limit reinvestment capacity and slow commercialization progress, creating execution risk across the next 2–6 months.

Negative Operating And Free Cash FlowRecurring negative operating and free cash flow indicate liquidity strain and reliance on non-operational funding. This reduces the company's ability to fund R&D, inventory or partner initiatives organically and may force capital-raising that dilutes strategic flexibility.

Volatile Profitability And Prior LossHistoric swings in net profitability, including a sizable loss, undermine predictability of earnings and cash generation. Such volatility complicates planning for hiring, marketing, and partnerships, and raises execution risk for sustaining growth initiatives over months.

Tsubota Laboratory Incorporated News

Tsubota Laboratory Swings to Heavy Loss as Revenue Plunges, Forecasts Deep Full-Year Deficit

Tsubota Laboratory Incorporated ( ($JP:4890) ) has shared an update. Tsubota Laboratory reported a sharp deterioration in non-consolidated...

3d ago

4890

Tsubota Laboratory’s Interim Financial Results Highlight Sustainable Growth Strategy

Tsubota Laboratory Incorporated ( ($JP:4890) ) has provided an announcement. Tsubota Laboratory Incorporated has announced its interim financial...

3M ago

4890

Tsubota Laboratory Reports Significant Revenue Decline and Net Loss

Tsubota Laboratory Incorporated ( ($JP:4890) ) has shared an update. Tsubota Laboratory Incorporated reported a significant decline in...

3M ago

4890

Tsubota Laboratory Reports First Quarter Losses Amidst Sales Decline

An update from Tsubota Laboratory Incorporated ( ($JP:4890) ) is now available. Tsubota Laboratory Incorporated reported a decrease...

6M ago

4890

Tsubota Laboratory Reports Strong Financial Recovery in FY2025

The latest announcement is out from Tsubota Laboratory Incorporated ( ($JP:4890) ). Tsubota Laboratory, Inc. reported significant financial...

9M ago

4890

Tsubota Laboratory’s Impressive Financial Turnaround in 2024

Tsubota Laboratory Incorporated (JP:4890) has released an update. Tsubota Laboratory, Inc. reports a significant increase in net sales...

1y ago

4890

4890 FAQ

What was Tsubota Laboratory Incorporated’s price range in the past 12 months?

Tsubota Laboratory Incorporated lowest stock price was ¥261.00 and its highest was ¥460.00 in the past 12 months.

What is Tsubota Laboratory Incorporated’s market cap?

Tsubota Laboratory Incorporated’s market cap is ¥7.04B.

When is Tsubota Laboratory Incorporated’s upcoming earnings report date?

Tsubota Laboratory Incorporated’s upcoming earnings report date is May 18, 2026 which is in 91 days.

How were Tsubota Laboratory Incorporated’s earnings last quarter?

Tsubota Laboratory Incorporated released its earnings results on Feb 13, 2026. The company reported -¥7.22 earnings per share for the quarter, missing the consensus estimate of N/A by -¥7.22.

Is Tsubota Laboratory Incorporated overvalued?

According to Wall Street analysts Tsubota Laboratory Incorporated’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Tsubota Laboratory Incorporated pay dividends?

Tsubota Laboratory Incorporated does not currently pay dividends.

What is Tsubota Laboratory Incorporated’s EPS estimate?

Tsubota Laboratory Incorporated’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Tsubota Laboratory Incorporated have?

Tsubota Laboratory Incorporated has 25,794,300 shares outstanding.

What happened to Tsubota Laboratory Incorporated’s price movement after its last earnings report?

Tsubota Laboratory Incorporated reported an EPS of -¥7.22 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.534%.

Which hedge fund is a major shareholder of Tsubota Laboratory Incorporated?

Currently, no hedge funds are holding shares in JP:4890

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Tsubota Laboratory Incorporated

Tsubota Laboratory Incorporated engages in the research and development of pharmaceuticals and medical devices for the treatment of myopia, dry eyes, and presbyopia. The company was incorporated in 2012 and is based in Tokyo, Japan.